Advertisement

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

22:36 EDT 20th May 2013 | BioPortfolio

Summary of "Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer."

Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Affiliation

Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. siqingfu@mdanderson.org.

Journal Details

This article was published in the following journal.

Name: Cancer
ISSN: 0008-543X
Pages: 1661-9

Links

Medical and Biotech [MESH] Definitions

Platinum

Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".

Chromatography, Reverse-phase

A chromatography technique in which the stationary phase is composed of a non-polar substance with a polar mobile phase, in contrast to normal-phase chromatography in which the stationary phase is a polar substance with a non-polar mobile phase.

Platinum Compounds

Inorganic compounds which contain platinum as the central atom.

Drug Resistance, Neoplasm

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Interphase

The interval between two successive CELL DIVISIONS during which the CHROMOSOMES are not individually distinguishable. It is composed of the G phases (G1 PHASE; G0 PHASE; G2 PHASE) and S PHASE (when DNA replication occurs).

PubMed Articles [ 19957 Associated PubMed Articles listed on BioPortfolio]

Disturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.

BACKGROUND: To explore novel platinum-based anticancer agents that are distinct from the structure and interaction mode of the traditional cisplatin by forming the bifunctional intrastrand 1,2 GpG add...

Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.

DNA methyltransferase 1 (DNMT1) promotes DNA methylation to maintain cancer drug resistance. The epigenetic drug, decitabine (DAC) is a potent hypomethylating agent, but its effect is transient becaus...

Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.

In our effort to investigate further texaphyrin conjugation as a means of increasing delivery and accumulation of known anticancer platinum agents in cancer cells, we have continued our studies on the...

Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.

PURPOSE: We aimed to identify primary platinum resistance in epithelial ovarian cancer (OC) patients with FIGO stage III-IV disease by an in vitro drug-response assay and to corr...

Formation of a bifunctional redox system using electrochemical reduction of platinum in ferrocene based ionic liquid and its reactivity with aryldiazonium.

The electrochemical reduction of platinum in ferrocene based ionic liquid, 1-ferrocenylethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide ([FcEMIM][TFSI]), has been investigated on both macro...

Clinical Trials [ 2994 Associated Clinical Trials listed on BioPortfolio]

SU5416 and Carboplatin to Treat Ovarian Cancer

SU5416, a novel antiangiogenesis agent, has been shown to be a potent and selective inhibitor of the tyrosine kinase activity of FlK-1 (a downstream effector of VEGF) in vitro and to inhib...

5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

The goal of this clinical research study is to find the highest safe dose of a combination of 5-azacytidine and oxaliplatin (a platinum-based chemotherapy drug) that can be given to patie...

Determination of Safe and Effective Dose of AMG 531 in Subjects With MDS Receiving Hypomethylating Agents

The purpose of this study is to evaluate the effect of AMG 531 on the incidence of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet transfusions) in...

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

The investigators hypothesize that, in addition to its apoptotic effect, clofarabine induces DNA hypomethylation. If the investigators' hypothesis is correct, findings from the present pro...

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemothe...

Search BioPortfolio:
Advertisement
Advertisement